Download Free Sample Report

The global Intraveno (IV) Iron Drugs market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.

The USA market for Global Intraveno (IV) Iron Drugs market is estimated to increase from USD million in 2022 to reach USD million by 2030, at a CAGR during the forecast period of 2023 through 2030.

The China market for Global Intraveno (IV) Iron Drugs market is estimated to increase from USD million in 2022 to reach USD million by 2030, at a CAGR during the forecast period of 2023 through 2030.

The Europe market for Global Intraveno (IV) Iron Drugs market is estimated to increase from USD million in 2022 to reach USD million by 2030, at a CAGR during the forecast period of 2023 through 2030.

Iron supplements are available in two forms: oral and intravenous. Intravenous iron preparations are superior to oral supplements, as these lead to higher and faster increase in iron and Hb levels. Oral supplements have disadvantages such as GI adverse events, poor adherence, poor gastrointestinal absorption, and non-compliance.
This report aims to provide a comprehensive presentation of the global market for Intraveno (IV) Iron Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Intraveno (IV) Iron Drugs. This report contains market size and forecasts of Intraveno (IV) Iron Drugs in global, including the following market information:

• Global Intraveno (IV) Iron Drugs Market Revenue, 2018-2023, 2024-2030, ($ millions)
• Global Intraveno (IV) Iron Drugs Market Sales, 2018-2023, 2024-2030, (Units)
• Global top five Intraveno (IV) Iron Drugs companies in 2022 (%)

Major drivers of the IV iron drugs market are increase in incidence of iron deficiency, rise in chronic kidney disease patients undergoing dialysis, and surging diabetic population. Increase in iron deficiency anemia in gynecology, oncology, and gastroenterology, noncompliance of oral therapy, and accurate, easy, and convenient access to IV iron dosages drive demand for intravenous iron drugs. However, complex approval process, stringent regulations, drug side effects, nutraceutical alternatives to prevent iron deficiency, and product price are likely to act as major restraints of the IV iron drugs market.
We surveyed the Intraveno (IV) Iron Drugs manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.

• Low Molecular Weight Iron Dextran
• Ferric Gluconate
• Iron Sucrose
• Ferric Carboxyl Maltose

• Hospitals
• Ambulatory Surgical Centers
• Diagnostic Centers

• North America (United States, Canada, Mexico)
• Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe)
• Asia-Pacific (China, India, Japan, South Korea, Australia, Rest of APAC)
• The Middle East and Africa (Middle East, Africa)
• South and Central America (Brazil, Argentina, Rest of SCA)

• Key companies Intraveno (IV) Iron Drugs revenues in global market, 2018-2023 (Estimated), ($ millions)
• Key companies Intraveno (IV) Iron Drugs revenues share in global market, 2022 (%)
• Key companies Intraveno (IV) Iron Drugs sales in global market, 2018-2023 (Estimated), (Units)
• Key companies Intraveno (IV) Iron Drugs sales share in global market, 2022 (%)

• Allergan
• AMAG Pharmaceuticals
• Galenica
• Actavis
• American Regent
• Sanofi
• Luitpold Pharmaceuticals
• Fresenius Medical Care
• Pharmacosmos
• Vifor Pharma

Outline of Major Chapters:
Chapter 1: Introduces the definition of Intraveno (IV) Iron Drugs, market overview.
Chapter 2: Global Intraveno (IV) Iron Drugs market size in revenue and volume.
Chapter 3: Detailed analysis of Intraveno (IV) Iron Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Intraveno (IV) Iron Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Intraveno (IV) Iron Drugs capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.